KR20230041071A - 항-인테그린 베타7 항체 제제 및 장치 - Google Patents

항-인테그린 베타7 항체 제제 및 장치 Download PDF

Info

Publication number
KR20230041071A
KR20230041071A KR1020237006223A KR20237006223A KR20230041071A KR 20230041071 A KR20230041071 A KR 20230041071A KR 1020237006223 A KR1020237006223 A KR 1020237006223A KR 20237006223 A KR20237006223 A KR 20237006223A KR 20230041071 A KR20230041071 A KR 20230041071A
Authority
KR
South Korea
Prior art keywords
hvr
formulation
seq
amino acid
acid sequence
Prior art date
Application number
KR1020237006223A
Other languages
English (en)
Korean (ko)
Inventor
제니퍼 풀리
메이나 타오 탕
스와티 톨
헬렌 티렐
메리암 아보우호세인
헤만트 아마르친타
오드리 보루프카
한 팅 딩
헤더 엘. 플로어스
글렌 스코트 기세
레나토 라바넬로
웬후이 장
Original Assignee
제넨테크, 인크.
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크., 에프. 호프만-라 로슈 아게 filed Critical 제넨테크, 인크.
Publication of KR20230041071A publication Critical patent/KR20230041071A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020237006223A 2020-07-31 2021-07-29 항-인테그린 베타7 항체 제제 및 장치 KR20230041071A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059427P 2020-07-31 2020-07-31
US63/059,427 2020-07-31
PCT/US2021/043690 WO2022026699A1 (en) 2020-07-31 2021-07-29 Anti-integrin beta7 antibody formulations and devices

Publications (1)

Publication Number Publication Date
KR20230041071A true KR20230041071A (ko) 2023-03-23

Family

ID=77693570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006223A KR20230041071A (ko) 2020-07-31 2021-07-29 항-인테그린 베타7 항체 제제 및 장치

Country Status (11)

Country Link
EP (1) EP4188958A1 (he)
JP (1) JP2023536158A (he)
KR (1) KR20230041071A (he)
AR (1) AR123085A1 (he)
AU (1) AU2021316017A1 (he)
BR (1) BR112023001734A2 (he)
CA (1) CA3190109A1 (he)
IL (1) IL300133A (he)
MX (1) MX2023001157A (he)
TW (1) TW202222832A (he)
WO (1) WO2022026699A1 (he)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
BRPI0908665A2 (pt) 2008-05-16 2020-08-18 Genentech Inc método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
WO2012151247A2 (en) * 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
CA2839493C (en) 2011-06-17 2016-02-09 Shl Group Ab Injection device
ES2619701T3 (es) 2011-06-17 2017-06-26 Shl Group Ab Dispositivo de inyección
WO2014160753A1 (en) 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
AR099856A1 (es) 2014-03-27 2016-08-24 Genentech Inc Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
AR103782A1 (es) * 2015-02-26 2017-05-31 Genentech Inc ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
WO2019246455A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Also Published As

Publication number Publication date
TW202222832A (zh) 2022-06-16
IL300133A (he) 2023-03-01
CA3190109A1 (en) 2022-02-03
AR123085A1 (es) 2022-10-26
WO2022026699A1 (en) 2022-02-03
AU2021316017A1 (en) 2023-02-16
BR112023001734A2 (pt) 2023-02-28
JP2023536158A (ja) 2023-08-23
MX2023001157A (es) 2023-02-22
EP4188958A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US11560434B2 (en) Formulation for anti-α4β7 antibody
US20210322546A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
KR101841527B1 (ko) 개선된 고농도 항－ＴＮＦα 항체 액체 제형
KR101994809B1 (ko) 항체 제제
RU2683861C2 (ru) Препараты однодоменных антигенсвязывающих молекул
KR102576012B1 (ko) 고농도 항-c5 항체 제형
JP2018507202A (ja) モノクローナル抗体のための安定的な液体製剤
US20230115617A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
US20130315913A1 (en) Anti-light antibody therapy for inflammatory bowel disease
US20170196837A1 (en) Formulations with reduced oxidation
TW202302640A (zh) 抗tl1a抗體組合物及肺中之治療方法
US10653779B2 (en) Formulations with reduced oxidation
US20240141051A1 (en) Methods for treating hand and foot dermatitis by administering an il-4r antagonist
KR20230041071A (ko) 항-인테그린 베타7 항체 제제 및 장치
US20160244520A1 (en) Compositions and methods for treating psoriatic arthritis
CN112955180A (zh) 含有抗pcsk9抗体的稳定制剂
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
CN113546252A (zh) 抗pcsk9抗体的药物递送装置
WO2023240223A2 (en) Anti-igf-1r antibody compositions
NZ617340B2 (en) Formulation for anti-?4?7 antibody